1. Home
  2. RNAC vs ANIK Comparison

RNAC vs ANIK Comparison

Compare RNAC & ANIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cartesian Therapeutics Inc.

RNAC

Cartesian Therapeutics Inc.

HOLD

Current Price

$7.94

Market Cap

168.3M

Sector

Health Care

ML Signal

HOLD

Logo Anika Therapeutics Inc.

ANIK

Anika Therapeutics Inc.

HOLD

Current Price

$14.85

Market Cap

197.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RNAC
ANIK
Founded
2007
1983
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
168.3M
197.6M
IPO Year
2016
1996

Fundamental Metrics

Financial Performance
Metric
RNAC
ANIK
Price
$7.94
$14.85
Analyst Decision
Strong Buy
Buy
Analyst Count
5
1
Target Price
$34.00
$17.00
AVG Volume (30 Days)
166.3K
97.6K
Earning Date
05-11-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
80.16
EPS
N/A
N/A
Revenue
$2,797,000.00
$112,819,000.00
Revenue This Year
N/A
$5.98
Revenue Next Year
N/A
$7.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.60
$7.90
52 Week High
$14.56
$16.24

Technical Indicators

Market Signals
Indicator
RNAC
ANIK
Relative Strength Index (RSI) 53.30 52.30
Support Level $6.71 $13.81
Resistance Level $8.39 $15.74
Average True Range (ATR) 0.58 0.91
MACD 0.08 0.01
Stochastic Oscillator 51.26 76.35

Price Performance

Historical Comparison
RNAC
ANIK

About RNAC Cartesian Therapeutics Inc.

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.

About ANIK Anika Therapeutics Inc.

Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.

Share on Social Networks: